Assessing patient and carer experiences in end-of-life care for gynecological cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the feasibility and acceptability of collecting data on patients' and carers' perceptions of care in the context of end-of-life (EOL) for individuals with advanced gynecological cancers. It focuses on understanding patient satisfaction, the importance of various aspects of care, and the experiences of carers during bereavement. The study will involve a cohort of patients who will complete questionnaires regarding their care experiences, and ideally, each patient will nominate a carer to participate as well. The data collected will help inform patient-centered EOL care practices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

A patient will be eligible for inclusion only if all of the following criteria are fulfilled:

1. Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician\*. Potential patient groups include, but are not limited to, those with platinum-resistant/refractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic/recurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade/undifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.
2. Patients may be on active cancer treatment, about to commence active cancer treatment or under observation/palliative care.
3. Age ≥ 18 years
4. Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).

Exclusion Criteria:

A patient will not be eligible for inclusion if any of the following criteria are fulfilled:

1. Unable to be comply with the protocol.
2. A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
3. Participation in another clinical trial.

A patient will be asked to appoint a carer.

Inclusion criteria carer:

1. Age ≥ 18 years
2. A relative or close friend who is actively supporting the patient in her illness
3. Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).

Exclusion criteria carer

A carer will not be eligible for inclusion if any of the following criteria are fulfilled:

1. Unable to be comply with the protocol
2. A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.

Where it's running

• The Norwegian Radium Hospital
  Oslo, Norway Recruiting

Study contacts

• Study coordinator: Kristina Lindemann, MD, PhD
• Email: klinde@ous-hf.no
• Phone: 004722934983

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using small devices to measure radiation dose during brachytherapy for cancer treatment

  This study is testing small devices that measure radiation during brachytherapy to see if they can help ensure patients with prostate and gynecological cancers receive the right amount of treatment safely.

  Recruiting East and North Hertfordshire NHS Trust · Northwood, Middlesex · NCT06863090

• Acupuncture to reduce chemotherapy-related nerve pain after gynecologic cancer

  This pilot will try acupuncture to see if it reduces chemotherapy-caused nerve pain (peripheral neuropathy) in people treated for gynecological cancers with carboplatin and paclitaxel.

  Recruiting The University of Hong Kong · Hong Kong · NCT06769061

• Body-fluid testing to detect early cancer in people at high risk

  This project will test whether different body-fluid tests can find early cancers in adults whose estimated 3-year risk of cancer is 4% or higher.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06907095

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Vaginal Biomarkers for Early Gynaecological Cancers

  This study tests whether markers in vaginal secretions differ between people with and without gynaecological cancers to help detect cancers earlier and monitor treatment.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton · NCT07622953

• HER2 expression across Brazilian gynecologic cancers

  This will test HER2 protein levels in tumor samples from adults with gynecologic cancers treated at Oncoclínicas sites to see how often HER2 is highly expressed.

  Recruiting AstraZeneca · São Paulo · NCT07101081

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.